Surveying microglia (also termed resting or ramified microglia) represent the predominant phenotypic state of microglia in the healthy adult brain. Unlike their activated counterparts, surveying microglia maintain a highly ramified morphology with dynamic processes that continuously scan the brain parenchyma. This perpetual surveillance allows them to rapidly detect and respond to pathological changes, making them critical sentinels of brain homeostasis[1].
Surveying microglia constitute approximately 10-15% of all brain cells and are distributed throughout the central nervous system (CNS). Despite being called resting, these cells are far from inactive—they actively monitor their microenvironment through constant process motility, extending and retracting their branches at approximately 2-4 μm per minute to survey a territory of approximately 15,000-20,000 μm³ per hour[2].
The surveillance behavior of microglia represents a remarkable feat of cellular organization:
Surveying microglia perform essential homeostatic functions:
| Marker | Expression | Function |
|---|---|---|
| IBA1 (AIF1) | High | Calcium-binding protein, actin reorganization |
| TMEM119 | High | Transmembrane protein, microglia-specific |
| P2RY12 | High | ADP receptor, process motility |
| CX3CR1 | High | Fractalkine receptor, neuron-microglia signaling |
| CD68 | Low | Lysosomal marker, increases with activation |
| TREM2 | Low-moderate | Triggering receptor on myeloid cells 2 |
Surveying microglia communicate with neurons through:
Even in resting state, microglia express receptors capable of detecting pathogens and damage:
Surveying microglia represent the first line of defense against amyloid pathology:
In PD, surveying microglia monitor dopaminergic neuron health:
Surveying microglia can transition to multiple activated phenotypes:
| Phenotype | Markers | Function |
|---|---|---|
| M1 (classical) | CD16, CD32, iNOS | Pro-inflammatory, antimicrobial |
| M2a (alternative) | CD206, Arg1 | Wound healing, tissue repair |
| M2b (type 2) | CD86 | Immunomodulation |
| M2c (acquired deactivation) | CD163 | Anti-inflammatory |
| Approach | Target | Status |
|---|---|---|
| CSF1R antagonists | Microglial depletion | Preclinical |
| TREM2 agonists | Phagocytosis enhancement | Clinical trials |
| CX3CR1 modulators | Neuron-microglia signaling | Preclinical |
| NLRP3 inhibitors | Inflammasome blockade | Preclinical |
The study of Surveying Microglia has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Hanisch & Kettenmann, Microglia: active sensor and versatile effector cells in the normal and pathologic brain (2007) ↩︎
Nimmerjahn et al., Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo (2005) ↩︎
Deczkowska et al., TREM2 as a regulator of microglial metabolism in Alzheimer's disease (2018) ↩︎